EA202190633A1 - Лекарственные формы для применения в педиатрии, способы получения и применения - Google Patents

Лекарственные формы для применения в педиатрии, способы получения и применения

Info

Publication number
EA202190633A1
EA202190633A1 EA202190633A EA202190633A EA202190633A1 EA 202190633 A1 EA202190633 A1 EA 202190633A1 EA 202190633 A EA202190633 A EA 202190633A EA 202190633 A EA202190633 A EA 202190633A EA 202190633 A1 EA202190633 A1 EA 202190633A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pediatrics
methods
dosage forms
obtaining
application
Prior art date
Application number
EA202190633A
Other languages
English (en)
Inventor
Прафул Балавант Дешпанде
Стефен Джеймс Квинлэн
Марта Голек
Джон Джерард О'Брайан
Джеймс Джозеф Макдоналд
Реем Эламеин Элсиддиг
Кен О'Ши
Original Assignee
Опко Айэлэнд Глобал Холдингз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Опко Айэлэнд Глобал Холдингз, Лтд. filed Critical Опко Айэлэнд Глобал Холдингз, Лтд.
Publication of EA202190633A1 publication Critical patent/EA202190633A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Описаны лекарственные формы соединения на основе витамина D для применения в педиатрии и формы с модифицированным высвобождением и способы их получения и применения.
EA202190633A 2018-08-31 2019-08-30 Лекарственные формы для применения в педиатрии, способы получения и применения EA202190633A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862725940P 2018-08-31 2018-08-31
PCT/IB2019/057360 WO2020044314A1 (en) 2018-08-31 2019-08-30 Vitamin d pediatric dosage forms, methods of making and using

Publications (1)

Publication Number Publication Date
EA202190633A1 true EA202190633A1 (ru) 2021-07-12

Family

ID=68165642

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190633A EA202190633A1 (ru) 2018-08-31 2019-08-30 Лекарственные формы для применения в педиатрии, способы получения и применения

Country Status (21)

Country Link
US (3) US11000480B2 (ru)
EP (1) EP3843706A1 (ru)
JP (1) JP2021535155A (ru)
KR (1) KR20210054539A (ru)
CN (1) CN112912067A (ru)
AU (4) AU2019329905B2 (ru)
BR (1) BR112021003788A2 (ru)
CA (1) CA3110020A1 (ru)
CL (2) CL2021000493A1 (ru)
CO (1) CO2021003805A2 (ru)
CR (1) CR20210158A (ru)
DE (1) DE202019005769U1 (ru)
EA (1) EA202190633A1 (ru)
EC (1) ECSP21021189A (ru)
IL (1) IL280937A (ru)
MX (1) MX2020011740A (ru)
PE (1) PE20211489A1 (ru)
PH (1) PH12021550413A1 (ru)
SG (1) SG11202101905YA (ru)
TW (1) TW202034905A (ru)
WO (1) WO2020044314A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116033940A (zh) 2020-04-06 2023-04-28 艾尔金制药有限公司 激活内源性抗菌药物治疗sars-cov-2感染
JP2023526980A (ja) 2020-05-31 2023-06-26 エアジェン ファーマ リミテッド ハードカプセル剤形及びその使用
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114176164A (zh) * 2021-12-17 2022-03-15 广东驱动力生物科技股份有限公司 反刍动物用水溶性抗应激助剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
CA2065603C (en) * 1991-04-09 2007-04-03 Hiroki Itoh Stabilized vitamin d preparation
JP3722832B2 (ja) * 1992-06-22 2005-11-30 ルーナー、コーポレーション 経口用１α−ヒドロキシプレビタミンＤ
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
EP3095447B1 (en) * 2006-02-03 2021-11-24 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
CN104523707B (zh) 2007-04-25 2022-08-26 欧普科Ip 控股Ii 有限公司 包含维生素d化合物和蜡质载体的口服控释组合物
CN101584683A (zh) * 2009-06-12 2009-11-25 沈阳药科大学 美托拉宗缓释胶囊及其制备方法
WO2012047098A1 (en) * 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
US9907758B2 (en) * 2012-01-09 2018-03-06 Panjab University Department Of Biotechnology (Dbt) Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US20160008377A1 (en) * 2014-07-12 2016-01-14 Aphios Corporation Formulations and compositions of vitamin d analogs for treating and preventing cancer and other diseases
CR20170085A (es) * 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
CN108420797B (zh) * 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法

Also Published As

Publication number Publication date
IL280937A (en) 2021-04-29
AU2019329905B2 (en) 2024-02-01
PH12021550413A1 (en) 2021-09-27
SG11202101905YA (en) 2021-03-30
AU2019329905A1 (en) 2021-03-18
EP3843706A1 (en) 2021-07-07
US20220000783A1 (en) 2022-01-06
KR20210054539A (ko) 2021-05-13
BR112021003788A2 (pt) 2021-06-08
CR20210158A (es) 2021-05-21
PE20211489A1 (es) 2021-08-11
MX2020011740A (es) 2021-04-19
ECSP21021189A (es) 2021-04-29
WO2020044314A1 (en) 2020-03-05
AU2024202877A1 (en) 2024-05-23
US11000480B2 (en) 2021-05-11
AU2021107168A4 (en) 2021-12-09
AU2021107174A4 (en) 2021-12-09
DE202019005769U1 (de) 2022-01-13
CA3110020A1 (en) 2020-03-05
US20210401752A1 (en) 2021-12-30
TW202034905A (zh) 2020-10-01
JP2021535155A (ja) 2021-12-16
CL2023002539A1 (es) 2024-02-23
CO2021003805A2 (es) 2021-04-19
US20200338006A1 (en) 2020-10-29
CL2021000493A1 (es) 2021-07-23
CN112912067A (zh) 2021-06-04

Similar Documents

Publication Publication Date Title
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
EA202190633A1 (ru) Лекарственные формы для применения в педиатрии, способы получения и применения
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201691991A1 (ru) Мультиспецифические антитела
BR112019012342A2 (pt) anticorpos il-11
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112019012343A2 (pt) anticorpos il-11ra
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CR20190271A (es) Anticuerpos antitau y métodos de uso
EA202191632A1 (ru) Ахромосомные динамические активные системы
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201792590A1 (ru) КОНЪЮГАТ АНТИТЕЛА ПРОТИВ ErbB2 И ЛЕКАРСТВЕННОГО СРЕДСТВА И ЕГО КОМПОЗИЦИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
PH12020551716A1 (en) Anti-ror antibody constructs
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades